Remove Competition Remove Pricing Remove San Diego Remove Venture Capital
article thumbnail

This Week in VC with Farb Nivi, Founder of Grockit

Both Sides of the Table

This was really a fun week at TWiVC because we decided to have an entrepreneur come and talk about raising capital rather than having a VC come on. In particular I tried to do most of the “entrepreneur advice on VC” up front so that if you don’t want to watch our views on the deals you don’t have to. They sponsor TWiVC.

article thumbnail

Bio Roundup: Dunsire’s Danish, Price Hikes, Rare-Disease Race & More

Xconomy

Our friend and one of our earliest employees, San Diego editor Bruce Bigelow, died suddenly last weekend. Bruce covered everything—and everyone—in San Diego’s innovation scene, including the life sciences. Xconomy was dumbstruck this week, and not by the fireworks overhead.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More

Xconomy

The field has gotten so competitive that multiple products are on the market for some diseases. An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12 percent a year between now and 2024, when they will account for an estimated 20 percent of worldwide prescription drug sales.

Pricing 97
article thumbnail

Pharmaceutical Price Controls Might Be Closer Than You Think

Xconomy

Amid the hue and cry over the Mylan EpiPen pricing debacle , Hillary Clinton unveiled her “ Plan to Respond to Unjustified Price Hikes for Long-Available Drugs. ” Clinton’s plan calls for “dedicated oversight to protect consumers.” That dependence on price increases won’t change any time soon. It has started.”

Pricing 40
article thumbnail

Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More

Xconomy

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug.

Pricing 79
article thumbnail

Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More

Xconomy

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. But the university also allowed them to patent the improvements they made, which enabled them to slap higher prices on each new version. to offer competitive pricing pressure.

Patents 77
article thumbnail

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Xconomy

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition. But such tools only work when companies play fair.

Pricing 79